{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:05:03Z","timestamp":1791273903354,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T00:00:00Z","timestamp":1387411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T00:00:00Z","timestamp":1387411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s40265-013-0168-2","type":"journal-article","created":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T02:43:12Z","timestamp":1387334592000},"page":"31-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":317,"title":["Ceftolozane\/Tazobactam: A Novel Cephalosporin\/\u03b2-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli"],"prefix":"10.1007","volume":"74","author":[{"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Zelenitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Denisuik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe R. S.","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred S.","family":"Gin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walkty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"3rd","given":"Joseph P.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,19]]},"reference":[{"issue":"1","key":"168_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2047-2994-1-11","volume":"1","author":"J Carlet","year":"2012","unstructured":"Carlet J, Jarlier V, Harbarth S, et al. Ready for a world without antibiotics? The Pensi\u00e8res antibiotic resistance call to action. Antimicrob Resist Infect Control. 2012;1(1):11.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"Suppl 1","key":"168_CR2","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1086\/655995","volume":"31","author":"LB Rice","year":"2010","unstructured":"Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol. 2010;31(Suppl 1):S7\u201310.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"168_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1086\/652237","volume":"50","author":"Infectious Diseases Society of America","year":"2010","unstructured":"Infectious Diseases Society of America. The 10\u00a0\u00d7\u00a0\u201920 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50(8):1081\u20133.","journal-title":"Clin Infect Dis."},{"issue":"12","key":"168_CR4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/cid\/cit152","volume":"56","author":"HW Boucher","year":"2013","unstructured":"Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10\u00a0\u00d7\u00a0\u201920 progress\u2014development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685\u201394.","journal-title":"Clin Infect Dis."},{"issue":"12","key":"168_CR5","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1358\/dof.2010.035.012.1541551","volume":"35","author":"G Perletti","year":"2010","unstructured":"Perletti G, Magri V, Wagenlehner FME, et al. CXA-101. Drugs Fut. 2010;35(12):977\u201386.","journal-title":"Drugs Fut."},{"issue":"7","key":"168_CR6","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/jac\/dkq143","volume":"65","author":"E Riera","year":"2010","unstructured":"Riera E, Macia MD, Mena A, et al. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. J Antimicrob Chemother. 2010;65(7):1399\u2013404.","journal-title":"J Antimicrob Chemother."},{"issue":"6","key":"168_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1469-0691.2007.01681.x","volume":"13","author":"N Mesaros","year":"2007","unstructured":"Mesaros N, Nordmann P, Plesiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect. 2007;13(6):560\u201378.","journal-title":"Clin Microbiol Infect."},{"issue":"9","key":"168_CR8","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1128\/AAC.00680-12","volume":"56","author":"B Moya","year":"2012","unstructured":"Moya B, Beceiro A, Cabot G, et al. Pan-beta-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother. 2012;56(9):4771\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"168_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.tim.2011.04.005","volume":"19","author":"EB Breidenstein","year":"2011","unstructured":"Breidenstein EB, de la Fuente-Nunez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19(8):419\u201326.","journal-title":"Trends Microbiol."},{"issue":"2","key":"168_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1128\/AAC.00834-09","volume":"54","author":"C Juan","year":"2010","unstructured":"Juan C, Zamorano L, P\u00e9rez JL, et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother. 2010;54(2):846\u201351.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"168_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1128\/AAC.00912-09","volume":"54","author":"CC Bulik","year":"2010","unstructured":"Bulik CC, Christensen H, Nicolau DP. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob Agents Chemother. 2010;54(1):557\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"168_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ijantimicag.2009.03.021","volume":"34","author":"DM Livermore","year":"2009","unstructured":"Livermore DM, Mushtaq S, Ge Y, et al. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents. 2009;34(5):402\u20136.","journal-title":"Int J Antimicrob Agents."},{"issue":"3","key":"168_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1128\/AAC.00860-06","volume":"51","author":"S Takeda","year":"2007","unstructured":"Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007;51(3):826\u201330.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"168_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijantimicag.2007.05.019","volume":"30","author":"S Takeda","year":"2007","unstructured":"Takeda S, Ishii Y, Hatano K, et al. Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007;30(5):443\u20135.","journal-title":"Int J Antimicrob Agents."},{"issue":"9","key":"168_CR15","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/j.1469-0691.2010.03130.x","volume":"16","author":"L Zamorano","year":"2010","unstructured":"Zamorano L, Juan C, Fern\u00e1ndez-Olmos A, et al. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010;16(9):1482\u20137.","journal-title":"Clin Microbiol Infect."},{"issue":"5","key":"168_CR16","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1128\/AAC.01737-10","volume":"55","author":"HS Sader","year":"2011","unstructured":"Sader HS, Rhomberg PR, Farrell DJ, et al. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 2011;55(5):2390\u20134.","journal-title":"Antimicrob Agents Chemother."},{"key":"168_CR17","first-page":"258","volume-title":"Wilson and Gisvold\u2019s textbook of organic medicinal and pharmaceutical chemistry","author":"J Beale","year":"2011","unstructured":"Beale J. Antibacterial antibiotics. In: Beale J, Block J, editors. Wilson and Gisvold\u2019s textbook of organic medicinal and pharmaceutical chemistry. 12th ed. Baltimore: Lippincott Williams & Wilkins; 2011. p. 258\u2013329.","edition":"12"},{"issue":"2","key":"168_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","volume":"73","author":"GG Zhanel","year":"2013","unstructured":"Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime\u2013avibactam: a novel cephalosporin\/beta-lactamase inhibitor combination. Drugs. 2013;73(2):159\u201377.","journal-title":"Drugs."},{"issue":"7","key":"168_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","volume":"69","author":"GG Zhanel","year":"2009","unstructured":"Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Drugs. 2009;69(7):809\u201331.","journal-title":"Drugs."},{"issue":"17","key":"168_CR20","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1016\/j.bmcl.2008.07.085","volume":"18","author":"A Toda","year":"2008","unstructured":"Toda A, Ohki H, Yamanaka T, et al. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg Med Chem Lett. 2008;18(17):4849\u201352.","journal-title":"Bioorg Med Chem Lett."},{"issue":"5","key":"168_CR21","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.bmc.2007.11.074","volume":"16","author":"K Murano","year":"2008","unstructured":"Murano K, Yamanaka T, Toda A, et al. Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure. Bioorg Med Chem. 2008;16(5):2261\u201375.","journal-title":"Bioorg Med Chem."},{"issue":"1","key":"168_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/CMR.00037-09","volume":"23","author":"SM Drawz","year":"2010","unstructured":"Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160\u2013201.","journal-title":"Clin Microbiol Rev."},{"issue":"2","key":"168_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0163-7258(99)00027-3","volume":"83","author":"Y Yang","year":"1999","unstructured":"Yang Y, Rasmussen BA, Shlaes DM. Class A beta-lactamases\u2014enzyme-inhibitor interactions and resistance. Pharmacol Ther. 1999;83(2):141\u201351.","journal-title":"Pharmacol Ther."},{"issue":"1","key":"168_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/157340911793743538","volume":"7","author":"KS Goo","year":"2011","unstructured":"Goo KS, Sim TS. Designing new beta-lactams: implications from their targets, resistance factors and synthesizing enzymes. Curr Comput Aided Drug Des. 2011;7(1):53\u201380.","journal-title":"Curr Comput Aided Drug Des."},{"issue":"2","key":"168_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1574-6976.2008.00105.x","volume":"32","author":"E Sauvage","year":"2008","unstructured":"Sauvage E, Kerff F, Terrak M, et al. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev. 2008;32(2):234\u201358.","journal-title":"FEMS Microbiol Rev."},{"issue":"2","key":"168_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1574-6976.2007.00095.x","volume":"32","author":"A Zapun","year":"2008","unstructured":"Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol Rev. 2008;32(2):361\u201385.","journal-title":"FEMS Microbiol Rev."},{"issue":"9","key":"168_CR27","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1128\/AAC.00296-10","volume":"54","author":"B Moya","year":"2010","unstructured":"Moya B, Zamorano L, Juan C, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54(9):3933\u20137.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"168_CR28","doi-asserted-by":"publisher","first-page":"e1000353","DOI":"10.1371\/journal.ppat.1000353","volume":"5","author":"B Moya","year":"2009","unstructured":"Moya B, Dotsch A, Juan C, et al. Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog. 2009;5(3):e1000353.","journal-title":"PLoS Pathog."},{"issue":"4","key":"168_CR29","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1128\/AAC.37.4.851","volume":"37","author":"K Bush","year":"1993","unstructured":"Bush K, Macalintal C, Rasmussen BA, et al. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother. 1993;37(4):851\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"168_CR30","unstructured":"Moulds N, Lister P. Impact of characterized resistance mechanisms on the susceptibility of Pseudomonas aeruginosa to CXA-101 [abstract no. C1-1415 plus poster]. 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2010; Boston."},{"issue":"3","key":"168_CR31","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1128\/AAC.01104-09","volume":"54","author":"B Moya","year":"2010","unstructured":"Moya B, Zamorano L, Juan C, et al. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother. 2010;54(3):1213\u20137.","journal-title":"Antimicrob Agents Chemother."},{"issue":"11","key":"168_CR32","doi-asserted-by":"publisher","first-page":"e27842","DOI":"10.1371\/journal.pone.0027842","volume":"6","author":"AM Lujan","year":"2011","unstructured":"Lujan AM, Macia MD, Yang L, et al. Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators. PLoS One. 2011;6(11):e27842.","journal-title":"PLoS One."},{"issue":"12","key":"168_CR33","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","volume":"57","author":"DJ Farrell","year":"2013","unstructured":"Farrell DJ, Flamm RK, Sader HS, et al. Antimicrobial activity of ceftolozane\/tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US hospitals (2011\u20132012). Antimicrob Agents Chemother. 2013;57(12):6305\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"168_CR34","unstructured":"Brown NP, Pillar CM, Sahm DF, et al. Activity profile of CXA-101 and CXA-101\/tazobactam against target Gram-positive and Gram-negative pathogens [abstract no. F1-1986 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"key":"168_CR35","unstructured":"Zhanel GG, Adam HJ, Walkty A, et al. In vitro activity of ceftolozane\/tazobactam tested against 1,705 Gram-negative pathogens isolated from patients in Canadian hospitals in 2011: CANWARD Surveillance Study [abstract no. E-200 plus poster]. 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 9\u201312 Sep 2012; San Francisco."},{"key":"168_CR36","unstructured":"Brown NP, Pillar CM, Draghi DC, et al. Activity Profile of CXA-101 against Gram-positive and Gram-negative pathogens by Broth and Agar dilution [abstract no. F1-354 plus poster]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 25\u201328 Oct 2008; Washington, DC."},{"key":"168_CR37","unstructured":"Livermore DM, Mushtaq S, Ge Y, et al. Activity of cephalosporin CXA-101 (FR264205) vs. P. aeruginosa [abstract no. F1-355 plus poster]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 25\u201328 Oct 2008; Washington, DC."},{"key":"168_CR38","unstructured":"Sader HS, Flamm RK, Jones RN. Activity of the novel antimicrobial combination ceftolozane\/tazobactam, tested against bacterial isolates in USA hospitals from patients with pneumonia (2011) [abstract no. 856 plus poster]. IDWeek 2012: a joint meeting of IDSA, SHEA, HIVMA, and PIDS; 17\u201321 Oct 2012; San Diego."},{"key":"168_CR39","unstructured":"Sader HS, Flamm RK, Farrell DJ, et al. Activity of the novel antimicrobial ceftolozane\/tazobactam (CXA-201) tested against contemporary clinical strains from European hospitals [abstract no. P1446]. Clin Microbiol Infect. 2012;18(Suppl. 3):382 (Plus poster presented at 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 Mar\u20133 Apr 2012; London)."},{"key":"168_CR40","unstructured":"Sader HS, Putnam SD, Jones RN. Activity of the novel cephalosporin CXA-101 tested in combination with tazobactam against cephalosporin-resistant Enterobacteriaceae, P. aeruginosa and B. fragilis [abstract no. F1-1992 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"key":"168_CR41","doi-asserted-by":"crossref","unstructured":"Livermore DM, Mushtaq S. Chequerboard titrations of cephalosporin CXA-101 (FR264205) and tazobactam vs. \u03b2-lactamase-producing Enterobacteriaceae [abstract no. F1-1994 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco.","DOI":"10.1093\/jac\/dkq248"},{"key":"168_CR42","unstructured":"Brown NP, Pillar CM, Sahm DF, et al. Disk diffusion testing of CXA-101 and CXA-101 in combination with tazobactam against target pathogens [abstract no. F1-1998 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"issue":"1","key":"168_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2011.02.004","volume":"70","author":"E Titelman","year":"2011","unstructured":"Titelman E, Karlsson IM, Ge Y, et al. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2011;70(1):137\u201341.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"168_CR44","unstructured":"Titelman E, Karlsson IM, Ge Y, et al. Activity of CXA-101 plus tazobactam against ESBL-producing Escherichia coli and Klebsiella pneumoniae [abstract no. F1-1993 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"key":"168_CR45","unstructured":"Killian SB, Knapp CC, Holliday NM, et al. An equivalency study of a sensititre dried MIC plate compared with the CLSI Broth microdilution reference method for CXA-201 and comparator antimicrobials [abstract no. D-691A plus poster]. 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 17\u201320 Sep 2011; Chicago."},{"key":"168_CR46","unstructured":"Moya B, Zamorano L, Juan C, et al. Activity of CXA-101 against Pseudomonas aeruginosa \u03b2-lactam resistance mechanisms: ampD, ampDh2, ampDh3, dacB (PBP4), and oprD mutations [abstract no. F1-1989 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"key":"168_CR47","unstructured":"Juan C, Zamorano L, P\u00e9rez JL, et al. Activity of the new cephalosporin CXA-101 (CXA) against carbapenem-resistant Pseudomonas aeruginosa (CR-PA) isolates from a Spanish Multicenter Study [abstract no. F1-1987 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"key":"168_CR48","unstructured":"Walkty A, Baxter M, Adam H, et al. In vitro activity of ceftolozane\/tazobactam (CXA-201) versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2011 [abstract no. 1616 plus poster]. IDWeek 2012: a joint meeting of IDSA, SHEA, HIVMA, and PIDS; 17\u201321 Oct 2012; San Diego."},{"key":"168_CR49","unstructured":"Cabot G, Macia MD, Gozalo M, et al. Activity of CXA-101 against a large collection of P. aeruginosa blood stream isolates overexpressing AmpC and the major efflux pumps [abstract no. E-816 plus poster]. 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2010; Boston."},{"key":"168_CR50","unstructured":"Brown SD, Traczewski MM. Quality control parameters for CXA-101 Broth microdilution susceptibility tests [abstract no. F1-1997 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"key":"168_CR51","unstructured":"Giske CG, Karlsson IM, Ge Y. CXA-101 (CXA) has high activity against clinical isolates of Pseudomonas aeruginosa including ceftazidime-resistant isolates [abstract no. F1-1988 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"key":"168_CR52","doi-asserted-by":"crossref","unstructured":"Zamorano L, Juan C, Fern\u00e1ndez-Olmos A, et al. Activity of the new cephalosporin CXA-101 against P. aeruginosa (PA) isolates from chronically infected cystic fibrosis patients [abstract no. F1-1991 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco.","DOI":"10.1111\/j.1469-0691.2009.03130.x"},{"key":"168_CR53","unstructured":"Snydman DR, Jacobus NV, McDermott LA. Activity of ceftolozane\/tazobactam (CXA-201) against 270 recent isolates from the Bacteroides group [abstract no. P1445]. Clin Microbiol Infect. 2012; 18(Suppl.3):382 (Plus poster presented at 22nd European Congress of Clinical Microbiology and Infectious Diseases; 31 Mar\u20133 Apr 2012; London)."},{"key":"168_CR54","unstructured":"Bulik CC, Christensen H, Nicolau DP. In vitro activity of CXA-101, a novel cephalosporin, against resistant phenotypes of Pseudomonas aeruginosa (PSA) [abstract no. 209 plus poster]. 47th Infectious Disease Society of America annual meeting; 29 Oct\u20131 Nov 2009; Philadelphia."},{"key":"168_CR55","unstructured":"Mushtaq S, Warner M, Ge J, et al. Activity of cephalosporin CXA-101 (FR264205) with \u03b2-lactamase inhibitors vs. Enterobacteriaceae [abstract no. F1-356 plus poster]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 25\u201328 Oct 2008; Washington, DC."},{"key":"168_CR56","unstructured":"Craig WA, Andes DA. In vivo activity of CXA-101 plus a 2:1, 4:1, or 8:1 ratio of tazobactam against various Enterobacteriaceae (ENT) producing extended-spectrum beta-lactamases (ESBLs) in the thighs of neutropenic mice [abstract no. F1-1999 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"issue":"4","key":"168_CR57","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1128\/AAC.01590-12","volume":"57","author":"WA Craig","year":"2013","unstructured":"Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013;57(4):1577\u201382.","journal-title":"Antimicrob Agents Chemother."},{"issue":"9","key":"168_CR58","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/jac\/dkq248","volume":"65","author":"DM Livermore","year":"2010","unstructured":"Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010;65(9):1972\u20134.","journal-title":"J Antimicrob Chemother."},{"issue":"8","key":"168_CR59","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1128\/AAC.01753-09","volume":"54","author":"Y Ge","year":"2010","unstructured":"Ge Y, Whitehouse MJ, Friedland I, et al. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother. 2010;54(8):3427\u201331.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"168_CR60","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1128\/AAC.06349-11","volume":"56","author":"B Miller","year":"2012","unstructured":"Miller B, Hershberger E, Benziger D, et al. Pharmacokinetics and safety of intravenous ceftolozane\u2013tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012;56(6):3086\u201391.","journal-title":"Antimicrob Agents Chemother."},{"key":"168_CR61","unstructured":"Miller B, Chandorkar G, Umeh O, et al. Safety and pharmacokinetics (PK) of intravenous (IV) ceftolozane\/tazobactam (C\/T) 3\u00a0g every 8 hours (q8h) and cumulative fraction of response (CFR) in plasma and epithelial lining fluid (ELF) in a simulated ventilator-associated pneumonia (VAP) population [abstract no. A-641 plus poster]. 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 9\u201312 Sep 2012; San Francisco."},{"issue":"6","key":"168_CR62","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1128\/AAC.35.6.1081","volume":"35","author":"R Wise","year":"1991","unstructured":"Wise R, Logan M, Cooper M, et al. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother. 1991;35(6):1081\u20134.","journal-title":"Antimicrob Agents Chemother."},{"key":"168_CR63","unstructured":"Hershberger E, Benziger D, Pheng LH, et al. Pharmacokinetics of CXA-101\/tazobactam in subjects with mild or moderate renal impairment [abstract no. P1519]. Clin Microbiol Infect. 2011;17(Suppl.4):S433 (Plus poster presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases; 7\u201310 May 2011; Milan)."},{"key":"168_CR64","unstructured":"Ge Y, Liao S. CXA-101 (CXA) population PK analysis and Monte Carlo (MC) Simulation for PK\/PD target attainment and dose regimen selection [abstract no. F1-2003 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"key":"168_CR65","unstructured":"Marier JF, Trinh M, Pheng LH, et al. Population PK analysis of intravenous CXA-101 in subjects with complicated urinary tract infection, including pyelonephritis [abstract no. PII-49 plus poster]. 112th annual meeting of the American Society for Clinical Pharmacology and Therapeutics; 2\u20135 Mar 2011; Dallas."},{"issue":"10","key":"168_CR66","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1093\/jac\/dks246","volume":"67","author":"G Chandorkar","year":"2012","unstructured":"Chandorkar G, Huntington JA, Gotfried MH, et al. Intrapulmonary penetration of ceftolozane\/tazobactam and piperacillin\/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012;67(10):2463\u20139.","journal-title":"J Antimicrob Chemother."},{"key":"168_CR67","unstructured":"Ceftolozane. Lexington: Cubist Pharmaceuticals; (Data on file); 2013."},{"key":"168_CR68","unstructured":"Brown NP, Pillar CM, Draghi DC, et al. Mode of action of CXA-101 based on minimum bactericidal concentration (MBC) analysis and Timekill kinetic (TK) analysis [abstract no. F1-358 plus poster]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 25\u201328 Oct 2008; Washington, DC."},{"key":"168_CR69","unstructured":"Jacqueline C, Desessard C, Le Mabecque V, et al. In vitro assessment using Time-Kill curves of CXA-101 (CXA)\/tazobactam (TAZ) against Escherichia coli (EC), Klebsiella pneumoniae (KP), and Pseudomonas aeruginosa (PA) strains [abstract no. F1-1996 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"key":"168_CR70","unstructured":"Soon RL, Forrest A, Holden PN, et al. In vitro pharmacodynamics of ceftolozane\/tazobactam against \u03b2-lactamase producing Escherichia coli (Ec) [abstract no. E-201 plus poster]. 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 9\u201312 Sep 2012; San Francisco."},{"issue":"1","key":"168_CR71","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1128\/AAC.01752-10","volume":"56","author":"CC Bulik","year":"2012","unstructured":"Bulik CC, Tessier PR, Keel RA, et al. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin\u2013tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother. 2012;56(1):544\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"168_CR72","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1128\/AAC.02513-12","volume":"57","author":"B VanScoy","year":"2013","unstructured":"VanScoy B, Mendes RE, Nicasio AM, et al. Pharmacokinetics\u2013pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother. 2013;57(6):2809\u201314.","journal-title":"Antimicrob Agents Chemother."},{"issue":"9","key":"168_CR73","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1128\/AAC.00461-13","volume":"57","author":"B VanScoy","year":"2013","unstructured":"VanScoy B, Mendes RE, Castanheira M, et al. Relationship between ceftolozane\u2013tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother. 2013;57(9):4134\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"168_CR74","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/jac\/dks343","volume":"68","author":"C Jacqueline","year":"2013","unstructured":"Jacqueline C, Roquilly A, Desessard C, et al. Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response. J Antimicrob Chemother. 2013;68(1):177\u201383.","journal-title":"J Antimicrob Chemother."},{"key":"168_CR75","unstructured":"Jacqueline C, Bretonniere C, Desessard C, et al. In vivo activity of CXA-101 against Pseudomonas aeruginosa (PA) in a rabbit experimental model of pneumonia: comparison with ceftazidime (CAZ), piperacillin\/tazobactam (TZP), and imipenem (IMP)\u00a0[abstract no. B-590 plus poster]. 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 17\u201320 Sep 2011; Chicago."},{"key":"168_CR76","unstructured":"Jacqueline C, Desessard C, Roquilly A, et al. 50% effective dose (ED50) determination of CXA-101 (CXA) alone or in combination with tazobactam (TAZ) for treating experimental peritonitis in mice due to extended-spectrum \u03b2-lactamase (ESBL)-producing Escherichia coli (EC) strains: comparison with ceftazidime (CAZ) and piperacillin\/tazobactam (TZP) [abstract no. F1-2000 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2009; San Francisco."},{"key":"168_CR77","unstructured":"Jacqueline C, Desessard C, Batard E, et al. ED50 determination of CXA-101 (CXA) alone and in combination with tazobactam (TAZ) for treating experimental peritonitis in mice due to ESBL-producing Klebsiella pneumoniae strains: comparison with ceftazidime (CAZ) and piperacillin\/tazobactam (TZP) [abstract no. B-708 plus poster]. 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2010; Boston."},{"key":"168_CR78","unstructured":"Umeh O, Cebrik D, Friedland I. A double-blind, randomized, phase 2 study to compare the safety and efficacy of intravenous CXA-101 (CXA) and intravenous ceftazidime (CTZ) in complicated urinary tract infection (cUTI)\u00a0[abstract no. L1-361A plus poster]. 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12\u201315 Sep 2010; Boston."},{"key":"168_CR79","unstructured":"Lucasti Umeh O, Cebrik D, Friedland I. A multicenter double-blind, randomized, phase 2 study to assess safety and efficacy of ceftolozane\/tazobactam (TOL\/TAZ) plus metronidazole (MTZ) compared to meropenem (MER) in adult patients with complicated intra-abdominal infections (cIAI). [abstract no. K-1709 plus poster]. 53th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 10\u201313 Sep 2013; Denver."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0168-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-013-0168-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0168-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0168-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:05:22Z","timestamp":1744700722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-013-0168-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,19]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["168"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0168-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,19]]},"assertion":[{"value":"19 December 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}